About: Chongqing Three Gorges Central Hospital

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chongqing Three Gorges Central Hospital Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

hospital in China

Attributes	Values
rdf:type	Item
description	griya sakit (jv) rumah sakik (min) rumoh sakét (ace) rumah sakit di Republik Rakyat Tiongkok (id) চীনের হাসপাতাল (bn) hospital in China (en) лікарня в Китаї (uk) مستشفى في الصين (ar)
rdfs:label	Chongqing Three Gorges Central Hospital (en) 三峡中心医院 (zh)
skos:prefLabel	Chongqing Three Gorges Central Hospital (en) 三峡中心医院 (zh)
name	Chongqing Three Gorges Central Hospital (en) 三峡中心医院 (zh)
ROR ID	wds:Q30269706-4CDD38E5-9D92-4330-9723-36648F7055F9
ROR ID	029v6mm06
instance of	wds:Q30269706-6155AC1C-AD70-4F64-9B67-D358209B7B36 wds:Q30269706-F395D9CE-E83F-4BA4-AFE8-787DFA268299
instance of	hospital medical organization
country	wds:Q30269706-20AE4026-7328-4C97-8180-5B2125B07BE3
country	China
inception	wds:Q30269706-F7257C79-6D25-423B-89AA-DFA2E24803E7
inception	1928-01-01 00:00:00Z (xsd:dateTime)
coordinate location	wds:Q30269706-DD8D177A-0654-481F-9FAD-064BB50DCC17
official website	wds:Q30269706-900A678C-BC1D-4941-9FE1-72AAB6348377
coordinate location	POINT(108.384062 30.804625)
official website	http://www.sx120.com.cn/
GRID ID	wds:Q30269706-46BBF490-4333-4074-9300-DC8734530563
GRID ID	grid.477128.f
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q30269706
is research site of	A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. China Registry of Non-disabling Ischemic Cerebrovascular Events Danhong Injection in the Treatment of Acute Ischemic Stroke Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients A Study Tislelizumab (BGB A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Cancer Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study G56W1 in Women With Postmenopausal Osteoporosis Mortality Study of Recombinant Human Neuregulin-1β to Treat Chronic Heart Failure (CHF) Patients
is research site of	wds:Q66045530-5A271210-D567-49A8-91C9-0D4B6F99ADAF wds:Q66073151-FFD04ABB-CD8C-4976-92F0-1835AC631DF4 wds:Q63572579-031C9DDD-AD10-4578-9C91-9BB98FC8FF01 wds:Q65360848-042A43D4-D597-4C94-A7C0-419DBA66996B wds:Q64189453-BB03DE53-DFFD-4B3C-A1A6-C7282CEC8939 wds:Q61974956-F85E17A4-77E8-4B3A-979D-E08FDDC4BC31 wds:Q97461652-E7A7B7ED-4ED9-416F-8D93-2FAAC0BDED7D wds:Q62062171-3268610E-197F-4261-945E-476406E25760 wds:Q64220362-33AB2FC3-D2A0-422A-9688-41C0E2D5632C wds:Q62039821-982AC7F8-2938-443D-8631-42C87A3C499D wds:Q66067044-F0F3728B-8D44-42E4-BE7F-F05A70205246
is employer of	Dong Peng Ran Yang Xiang Li Wenbing Zeng Xing Gui Liao
is educated at of	Dong Peng
is employer of	wds:Q96308371-27AE508B-9130-47C7-BEA1-ED96F466ED4E wds:Q96308370-7FB64023-2DA3-4DB9-A8F0-605C263B461F wds:Q96079778-120EC69E-006C-4668-BA2B-0C1225ACF62A wds:Q96308365-4C97981B-A045-445D-8B04-CB2031265553 wds:Q86944841-F08A48A9-9EFB-4E8D-8C00-FA14FF947949
is educated at of	wds:Q96079778-687E9267-10EE-4AA6-88DA-64A59239FE93

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software